Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | SMARCA4 |
Variant | negative |
Impact List | unknown |
Protein Effect | loss of function |
Gene Variant Descriptions | SMARCA4 negative indicates a lack of the SMARCA4 gene, mRNA, and/or protein. |
Associated Drug Resistance | |
Category Variants Paths |
SMARCA4 mutant SMARCA4 inact mut SMARCA4 negative |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
SMARCA4 negative | Advanced Solid Tumor | predicted - sensitive | Tazemetostat | Phase I | Actionable | In a Phase I trial, Tazemetostat (EPZ-6438) demonstrated safety and preliminary efficacy, resulted in clinical benefit (stable disease or better) in 38% (5/13) of patients with SMARCB1 or SMARCA4-negative advanced solid tumors (PMID: 29650362; NCT01897571). | 29650362 |
SMARCA4 negative | rhabdoid cancer | predicted - sensitive | Tazemetostat | Case Reports/Case Series | Actionable | In a Phase I trial, Tazemetostat (EPZ-6438) demonstrated safety and preliminary efficacy, resulted in 1 partial response and 1 durable stable disease in patient with SMARCA4-negative malignant rhabdoid tumor of the ovary (PMID: 29650362; NCT01897571). | 29650362 |